{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-038715","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.833886+00:00","generated_at":"2026-06-11T23:55:47.241401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023","bullets":["Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.","Cash & short-term investments $2.4B; issued $575M notes due 2028 at 1.75%, repurchased $434M of 2024 notes.","Eplontersen Phase 3 shows improvement through 85 weeks; PDUFA date Dec 22, 2023.","Donidalorsen OASIS-HAE and eplontersen CARDIO-TTRansform enrollment complete; data H1:2024 and H1:2025.","SPINRAZA royalties flat at $61M in Q2; Biogen's QALSODY approved for SOD1-ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-038715","json":"https://secwatch.observer/filing/0001140361-23-038715.json","markdown":"https://secwatch.observer/filing/0001140361-23-038715.md","text":"https://secwatch.observer/filing/0001140361-23-038715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/0001140361-23-038715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/brhc20057227_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:55:47.241401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1915dc48c9ee26bec50c29e0948e89ce8c48aa2","claim":"IONIS PHARMACEUTICALS INC reported financial results for second quarter 2023; six months ended June 30, 2023.","evidence_excerpt":"Ionis reports second quarter 2023 financial results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/0001140361-23-038715-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023; six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}